FDA 2026 Draft Guidance on Alternatives to Animal Testing
The FDA's March 2026 draft guidance on alternatives to animal testing marks a pivotal shift in preclinical drug development. Here's what pharma R&D teams need to know.
Optimising Preclinical Pharmacology for Oncology NMEs
Over 90% of oncology NMEs that succeed in animal studies fail in clinical trials. This analysis examines how to optimise preclinical pharmacology models to improve translational success.
Success for Non-Animal Testing of Preclinical Toxicity?
Can non-animal testing methods be used in preclinical drug discovery? Here is what the evidence is for their accuracy and limits assessing preclinical toxicity.
Good Laboratory Practice Always Sets the R&D Standard
Good Laboratory Practice strengthens data integrity, reproducibility, and regulatory confidence across pharma non-clinical R&D and preclinical research.
Strategic Pharma Intelligence Drives Better Decisions in Life Sciences
Find out why strategic pharma intelligence is needed to connect insights and to guide confident decision-making across the drug development lifecycle.
Why the U.S. Medicine Supply Chain Is One Shortage Away from Crisis
The USP's 2025 Vulnerable Medicines List flags 100 drugs at high risk. Here is what to do to build pharma supply chain resilience.